Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C12H15N5O2S · HCl
CAS Number:
Molecular Weight:
329.81
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
assay
≥98% (HPLC)
form
powder
color
white
solubility
H2O: 10 mM, ethanol: 10 mg/mL
storage temp.
−20°C
SMILES string
Cl.NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12
InChI
1S/C12H15N5O2S.ClH/c13-12(14)16-6-7-17-20(18,19)11-3-1-2-9-8-15-5-4-10(9)11;/h1-5,8,17H,6-7H2,(H4,13,14,16);1H
InChI key
GUGJQAFPKZZOIV-UHFFFAOYSA-N
Biochem/physiol Actions
Shown to be an intracellular calcium antagonist. Reported to induce neurite formation.
Storage Class
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
H Tsushima et al.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 8(12), 1317-1328 (1998-01-07)
Erythropoietin (Epo) is a cytokine known to stimulate proliferation and differentiation of erythroid cells. However, recent gene disruption experiments demonstrated that Epo receptor signaling is not an obligatory step in erythroid differentiation. Here, we describe the role of Epo in
M R Crowley et al.
Journal of cardiovascular pharmacology, 23(5), 806-813 (1994-05-01)
HA1004, an isoquinolinesulfonamide and a cyclic nucleotide-dependent protein kinase inhibitor, is an intracellular calcium antagonist that produces vascular smooth muscle (VSM) relaxation in vitro. We studied the hemodynamic effects of intravenous (i.v.) infusions of HA1004 (0.1-2.0 mg/kg) in vivo in
A Fex Svenningsen et al.
Journal of neuroscience research, 52(5), 530-537 (1998-06-19)
Schwann cell proliferation was studied in cultured segments of the rat sciatic nerve by measurement of [3H] thymidine incorporation or through bromodeoxyuridine-(BrdU)-labelling and immunocytochemistry. The aim was to delineate mechanisms involved in the injury-induced proliferative response of Schwann cells. Removal